Should Health-Care Systems Pay for Replacement Therapy in Patients With Alpha1-Antitrypsin Deficiency? A Critical Review and Cost-Effectiveness Analysis

Stephan A. Alkins, MD and Patrick O'Malley, MD, MPH From the Pulmonary and Critical Care Medicine Service (Dr. Alkins) and the Department of Internal Medicine (Dr. O'Malley), Walter Reed Army Medical Center, Washington, DC.


CHEST. 2000;117(3) 

In This Article


Abbreviations: alpha1-AT = alpha1-antitrypsin; LE = life expectancy; LEtreated = life expectancy of treated subjects; LEuntreated = life expectancy of untreated subjects; NIH = National Institutes of Health

The views expressed herein are those of the authors and do not necessarily reflect the views of the U.S. Army or the Department of Defense.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.